Compare Banco Bilbao Vizcaya Argentaria SA (BBVA) vs Quest Diagnostics Inc (DGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Banco Bilbao Vizcaya Argentaria SA vs Quest Diagnostics Inc — how do they compare? Banco Bilbao Vizcaya Argentaria SA trades at $28.54 (market cap $157.51B), while Quest Diagnostics Inc trades at $238.02 (market cap $26.21B). The key difference: Banco Bilbao Vizcaya Argentaria SA is far larger — about 6× Quest Diagnostics Inc's market cap, and Banco Bilbao Vizcaya Argentaria SA pays the higher dividend (3.8%). Which is the better fit depends on your goals.
| BBVA | DGX | |
|---|---|---|
Market Cap | $157.51B | $26.21B |
Sector | Financials | Health |
52-Week High | $28.50 | $238.50 |
52-Week Low | $17.96 | $173.49 |
Dividend Yield | 3.8% | 1.45% |
Enterprise Value | — | $31.97B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BBVA trades at $28.535, up 0.65% with bullish technical signals from moving averages. The bank reported strong Q2 2026 results with net profit rising 11.4% year-over-year and announced a $2.3 billion share buyback program. Revenue reached $39.42 billion in 2025 with net income margin of 26.13% and ROE of 18.5%. Analyst consensus leans bullish with 7 buy ratings among 13 analysts.
Outlook remains positive with improved profitability guidance and strategic leadership reshuffling. Key risks include ongoing antitrust investigations in Spain and potential economic divergence in core markets. The stock offers attractive valuation with P/E of 12.98x, though recent RSI levels suggest potential near-term consolidation.
Quest Diagnostics (DGX) trades at $237.24, down 0.16% on the day, with a bullish technical signal from moving averages. The company reported strong Q2 2026 earnings, beating estimates with EPS of $3.12 and raising its full-year outlook, driven by robust testing demand. Revenue grew to $11.04B in 2025, with net income of $992M, though margins face pressure from lower-margin deals and rising costs.
The outlook is positive due to raised guidance and AI integration enhancing efficiency, but risks include debt levels and margin compression. Analysts maintain a cautious buy stance with a $249.50 price target, indicating modest upside potential from current levels amid competitive and cost challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Banco Bilbao Vizcaya Argentaria SA
Despite its Spanish origins, BBVA generates three quarters of its profits in emerging markets, especially Mexico that contributes nearly half of BBVA's net profit. BBVA is overwhelmingly a retail and commercial bank with corporate and investment banking forming a smaller part of the overall business.
Read more on BBVA →About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →
